CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are rare malignancies characterized by resistance to chemotherapy and poor clinical outcomes. While immunotherapy have shown promise, especially in the first-line treatment, effective therapeutic strategies for patients with PD-L1-negat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ünal Metin Tokat, Şevval Nur Bilgiç, Ashkan Adibi, Esranur Aydın, Onur Tutar, Hilal Cansız, Ali Yılmaz Altay, Nalan Akgul Babacan, Eylül Özgü, Alina Melisa Manea, Mutlu Demiray
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-05-01
Edice:	Frontiers in Immunology
Témata:	Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) immunotherapy CDK4/6 inhibitor precision oncology pembrolizumab ipilimumab
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1858358/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!